Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / MDRX - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veradigm Inc. (MDRX) | Benzinga


MDRX - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veradigm Inc. (MDRX) | Benzinga

  • LOS ANGELES, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming January 22, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ:MDRX) common stock between February 26, 2021 and June 13, 2023, inclusive (the "Class Period").

    If you suffered a loss on your Veradigm investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Veradigm-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

    On February 28, 2023, Veradigm disclosed that it "detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to reported revenues during those periods." As a result, the Company reported that it expects "a reduction in revenue from continuing operations of approximately $20 million dollars in the aggregate from what it otherwise reported since the 3rd quarter of 2021 and expected to report for the 4th quarter of 2022." The Company added that it is "continuing to evaluate the materiality of the mis-statement to determine if the full amount of this adjustment will flow through in the 4th quarter of 2022 or if prior periods will also require adjustment." As a result, Veradigm revised its 2023 ...

    MDRX)>Full story available on Benzinga.com

  • Stock Information

    Company Name: Allscripts Healthcare Solutions Inc.
    Stock Symbol: MDRX
    Market: NASDAQ
    Website: allscripts.com

    Menu

    MDRX MDRX Quote MDRX Short MDRX News MDRX Articles MDRX Message Board
    Get MDRX Alerts

    News, Short Squeeze, Breakout and More Instantly...